Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Ionis Pharmaceuticals won approval from the Food and Drug Administration on ...
Alnylam (ALNY), and BioMarin Pharmaceutical (BMRN) were among the gainers on Tuesday after Citi launched the SMid Cap Biotech group with a bullish view, citing compelling growth and catalyst outlook.
An Ionis Pharmaceuticals drug has preliminary data showing it met the main goal of its pivotal test in a rare disease with only a handful of approved treatments. With these results in hand, Ionis is ...
A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the ...
BridgeBio Pharma (NASDAQ:BBIO) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on ...
How Ionis Pharmaceuticals Stock Has Been Trading Ionis Pharmaceuticals (IONS) has drawn investor attention recently as the stock moved 2.3% in the latest session, with shorter term returns differing ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from ...
Ionis Pharmaceuticals has revenue from commercialized medicines, but those products reached the market in the hands of biopharma industry partners. The genetic medicines company does have wholly owned ...
Ionis Pharmaceuticals (IONS) trades at $72.70 with Barclays raising its price target to $106, citing a projected $4 billion peak sales opportunity for olezarsen in severe hypertriglyceridemia with a ...
On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...
Eli Lilly Earnings: Revenue Increases Reflect Global Demand for Oral Obesity Therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results